<?xml version="1.0" ?>
<document id="26d93683447b88c154664f5f80b35cd7991ba106">
  <chunk id="26d93683447b88c154664f5f80b35cd7991ba106.c0" text="The Anti-Porcine Parvovirus Activity of Nanometer Propolis Flavone and Propolis Flavone In Vitro and In Vivo">
    <entity charOffset="59-66" id="26d93683447b88c154664f5f80b35cd7991ba106.c0.e0" ontology_id="CHEBI_42491" text="Flavone" type="chemical"/>
    <entity charOffset="80-87" id="26d93683447b88c154664f5f80b35cd7991ba106.c0.e1" ontology_id="CHEBI_42491" text="Flavone" type="chemical"/>
  </chunk>
  <chunk id="26d93683447b88c154664f5f80b35cd7991ba106.c1" text="Objectives. The present study was conducted to evaluate the activity of nanometer propolis flavone (NPF) on inhibiting porcine parvovirus (PPV) in vitro and in vivo. Methods. In vitro, the effect of NPF on cellular infectivity of PPV was carried out before and after adding drug and simultaneous adding and PPV after being mixed. In vivo, the anti-PPV effect of NPF in guinea pigs was performed. Results. The results showed that NPF could significantly inhibit PPV infecting porcine kidney-(PK-) 15 cells compared with propolis flavone (PF), and the activity of NPF was the best in preadding drug pattern. NPF at high and medium doses was able to observably restrain PPV copying in lung, gonad, blood, and spleen, decrease the impact of PPV on weight of guinea pigs, and improve hemagglutination inhibition (HI) of PPV in serum. In addition, it could also increase the contents of IL-2 and IL-6 in serum after PPV challenge. Conclusion. These results indicated that NPF could significantly improve the anti-PPV activity of PF, and its high concentration possessed the best efficacy. Therefore, NPF would be expected to be exploited into a new-style antiviral drug.">
    <entity charOffset="91-98" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e0" ontology_id="CHEBI_42491" text="flavone" type="chemical"/>
    <entity charOffset="139-142" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e1" ontology_id="CHEBI_53261" text="PPV" type="chemical"/>
    <entity charOffset="230-233" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e2" ontology_id="CHEBI_53261" text="PPV" type="chemical"/>
    <entity charOffset="274-278" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e3" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="307-310" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e4" ontology_id="CHEBI_53261" text="PPV" type="chemical"/>
    <entity charOffset="461-464" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e5" ontology_id="CHEBI_53261" text="PPV" type="chemical"/>
    <entity charOffset="528-535" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e6" ontology_id="CHEBI_42491" text="flavone" type="chemical"/>
    <entity charOffset="592-596" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e7" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="667-670" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e8" ontology_id="CHEBI_53261" text="PPV" type="chemical"/>
    <entity charOffset="737-740" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e9" ontology_id="CHEBI_53261" text="PPV" type="chemical"/>
    <entity charOffset="815-818" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e10" ontology_id="CHEBI_53261" text="PPV" type="chemical"/>
    <entity charOffset="910-913" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e11" ontology_id="CHEBI_53261" text="PPV" type="chemical"/>
    <entity charOffset="1149-1158" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e12" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="1159-1163" id="26d93683447b88c154664f5f80b35cd7991ba106.c1.e13" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
  </chunk>
</document>
